Skip to main
BDTX
BDTX logo

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is poised for significant growth due to its robust pipeline, particularly the promising therapies BDTX-4933 and BDTX-1535 targeting oncogenic mutations. The company's recent findings, including a 60% clinical overall response rate (cORR) for silevertinib and the potential to capture a lucrative first-line non-small cell lung cancer (NSCLC) market exceeding $1 billion, further substantiate a positive outlook on its stock. Additionally, anticipated value inflection points from upcoming trials could enhance investor confidence, driving substantial upside in the company’s valuations.

Bears say

The financial outlook for Black Diamond Therapeutics Inc. is compromised by reduced confidence in the replicability of reported outcomes related to its drug silevertinib, particularly at lower dosing levels. Additionally, the overall efficacy metrics are underwhelming, with the company's clinical results falling short in comparison to competing drugs, such as firmo's cORR in phase 3 trials. The current market capitalization of approximately $230 million reflects a bearish sentiment towards the company's prospects, driven by concerns over its competitive positioning and potential enrollment discrepancies in its clinical trials.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.